Quince Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 32
- Market Cap
- $29.8M
- Website
- http://quincetx.com
- Introduction
Quince Therapeutics, Inc.(formerly Cortexyme, Inc.） is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline composed of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Open-Label Extension of EryDex Study IEDAT-04-2022
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Quince Therapeutics S.p.A.
- Target Recruit Count
- 106
- Registration Number
- NCT06664853
- Locations
- 🇺🇸
University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence, Los Angeles, California, United States
🇺🇸The Johns Hopkins Hospital, Division of pediatric allergy and immunology, Baltimore, Maryland, United States
🇺🇸Biotrial Inc., Newark, New Jersey, United States
Evaluate the Neurological Effects of EryDex on Subjects With A-T
- Conditions
- Ataxia Telangiectasia
- Interventions
- Other: Placebo
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Quince Therapeutics S.p.A.
- Target Recruit Count
- 106
- Registration Number
- NCT06193200
- Locations
- 🇺🇸
University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence, Los Angeles, California, United States
🇺🇸The Johns Hopkins Hospital, Division of pediatric allergy and immunology, Baltimore, Maryland, United States
🇺🇸Biotrial Inc., Newark, New Jersey, United States
Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study
- Conditions
- Ataxia TelangiectasiaGenetic Syndrome
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Quince Therapeutics S.p.A.
- Target Recruit Count
- 104
- Registration Number
- NCT03563053
- Locations
- 🇮🇳
Vijaya Health Centre, Department of Neurology, Chennai, Tamil Nadu, India
🇳🇴Norwegian National Unit for Newborn Screening, Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
🇬🇧Nottingham University Hospitals NHS Trust - Queen's Medical Centre, Nottingham, Nottinghamshire, United Kingdom
Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients
- Conditions
- Nervous System DiseaseGenetic Syndrome
- Interventions
- Drug: EryDex Low dose DSPDrug: EryDex High dose DSPDrug: Pooled Placebo
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Quince Therapeutics S.p.A.
- Target Recruit Count
- 176
- Registration Number
- NCT02770807
- Locations
- 🇺🇸
UCLA-Ataxia Center and HD Center of Exellence, Los Angeles, California, United States
🇺🇸The Ataxia-Telangiectasia Clinical Center, The Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Recovery and Survival of EryDex in Non-patient Volunteers
- Conditions
- Healthy
- Interventions
- Drug: DSP loaded RBC using EryDex SystemDrug: Sham treated RBC using the EryDex System
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2016-02-01
- Lead Sponsor
- Quince Therapeutics S.p.A.
- Target Recruit Count
- 10
- Registration Number
- NCT02380924
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
- Prev
- 1
- 2
- Next
News
Quince Therapeutics Strengthens Scientific Advisory Board with Leading Immunologist Ahead of Phase 3 Results
Quince Therapeutics appointed Dr. Hassan Abolhassani, a top-cited immunologist from Karolinska Institutet, to its Scientific Advisory Board as the ninth expert member.
Quince Therapeutics Secures Up to $22 Million to Advance Phase 3 Ataxia-Telangiectasia Trial
Quince Therapeutics raised $11.5 million in upfront proceeds with potential for an additional $10.4 million through warrant exercises to fund operations into 2026.
Quince Therapeutics' Phase 3 NEAT Trial for Ataxia-Telangiectasia Reaches 50% Enrollment Milestone
Quince Therapeutics has enrolled 46 participants in its Phase 3 NEAT trial evaluating EryDex for Ataxia-Telangiectasia treatment, with completion expected in Q2 2025 and topline results by year-end.
Quince Therapeutics' EryDex Phase 3 Trial for Ataxia-Telangiectasia Nears Enrollment Completion
Quince Therapeutics' Phase 3 NEAT trial of EryDex for Ataxia-Telangiectasia (A-T) is expected to complete enrollment in Q2 2025, marking a significant milestone.
Quince Therapeutics Presents Phase 3 ATTeST Trial Safety Data for EryDex in Ataxia-Telangiectasia
Quince Therapeutics presented safety data from the Phase 3 ATTeST trial of EryDex for Ataxia-Telangiectasia (A-T) at the Child Neurology Society Annual Meeting.
EryDex Shows Long-Term Safety in Pediatric Ataxia-Telangiectasia Patients
Quince Therapeutics' EryDex demonstrates a favorable long-term safety profile in pediatric patients with Ataxia-Telangiectasia (A-T) over a minimum of 24 months.